Interestingly, the median onset of response after HIT-IT with T-VEC was 3.1 months, which is even later than after treatment with ICIs such as nivolumab (anti-PD1 mAb), where the median time to response takes 2.2 months; both time points were obtained in phase III clinical trials in melanoma patients (33, 37, 38). The gene discussed is PDCD1; the disease is melanoma.